This might be explained by changes in conventional treatment strategies for CKD–mineral and bone disorder, from the time of earlier studies to the time period of the current study, including the publication of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative guidelines on bone and mineral metabolism [58] and the approval of cinacalcet by the Swedish Medical Products Agency, both of which could have influenced treatment strategies towards a more pronounced PTH suppression. The gene discussed is PTH; the disease is bone disorder.